Pfizer Sees Deeper Price Cuts, Lilly Maintains China Momentum – Emerging Market Earnings Roundup (Part 2)
This article was originally published in PharmAsia News
Pfizer said that it has plans to rebound from a volatile fourth quarter of price cuts and slower than expected volume gains in emerging markets. Eli Lilly hopes to build on gains in China and boost volume growth overall in emerging markets to shore up revenues after major patents expired in key countries.
You may also be interested in...
Post-Lipitor Pfizer Will Have Two Business Models: Innovation And Value
Pfizer CEO Ian Read provided Wall Street with more clarity on his vision for the company as it moves beyond Lipitor into a new era. Pfizer will have two primary businesses, he said, an innovative pharmaceutical engine and a value business.
Pfizer's Salomon Azoulay And Bing Yan On Prevenar, Partnering In China Post-Lipitor: An Interview With PharmAsia News (Part 2 of 2)
Pfizer Inc. CEO Ian Read recently affirmed Pfizer's commitment to emerging markets, choosing to keep its established products unit in-house even as he looks to divest non-core assets like the animal health and nutrition business units. Just one week after the announcement of Read's plan, Salomon Azoulay, Pfizer's senior VP for medical & development emerging markets, and Pfizer China Vaccines Lead Bing Yan sat down with PharmAsia News' Shanghai Bureau to talk about Pfizer's blockbuster vaccines Prevenar and Prevenar 13 - marketed in the U.S. as Prevnar - in what will be the world's largest vaccines market. Azoulay was in town to explore partnerships in China, a topic he also discusses in this interview, as well as the importance of physician education in emerging markets.
Are Emerging Markets Part Of Big Pharma's Core Business?
As Big Pharma companies increasingly look to emerging markets to capture some of the growth lost from the patent cliff in the U.S. and Europe, they are also shifting focus more to branded generics, leaving some investors to question whether companies would be better off spinning out their emerging market units, which would leave behind smaller companies focused on the core business of developing and marketing innovative therapies